Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.31 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | FYN | P06241 | 1/20 | 0.31 |
| ▸ | LYN | P07948 | 1/20 | 0.31 |
| ▸ | SRC | P12931 | 1/20 | 0.31 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8056850 | 0.94 | ALDH1A1 (0.33) | ALDH1A1CYP2D6CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL8044726 | 0.92 | ALDH1A1 (0.32) | ALDH1A1CYP2D6CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL3111009 | 0.91 | TSHR (0.32) | ALDH1A1CYP2D6CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL477125 | 0.91 | ALDH1A1 (0.37) | ALDH1A1CYP2D6CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL477124 | 0.91 | ALDH1A1 (0.37) | ALDH1A1CYP2D6CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL477126 | 0.91 | ALDH1A1 (0.37) | ALDH1A1CYP2D6CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL8062420 | 0.86 | CXCR4 (0.30) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL8060449 | 0.85 | ALDH1A1 (0.33) | ALDH1A1CYP2D6CYP3A4CYP1A2HSD17B10 | |
| SCHEMBL8057783 | 0.84 | — | — | |
| SCHEMBL769901 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-04-14 | — | — | US | claimed |
| EP-3849974-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | claimed |
| WO-2020052738-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2020-03-19 | — | — | WO | claimed |
| EP-2170889-B1 | 6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-08-17 | — | — | EP | claimed |
| US-8846676-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-09-30 | — | — | US | claimed |
| US-8354405-B2 | 6-cycloamino-3-(pyrid-4-yl)imidazo[1,2-b]pyridazine derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-01-15 | — | — | US | claimed |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | US | claimed |
| WO-2024150146-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES | NOVARTIS AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| WO-2023238078-A1 | (S)-ENGINEERED OXYNITRILASE POLYPEPTIDES AND USES THEREOF | NOVARTIS AG (CH) | 2023-12-14 | — | — | WO | disclosed |
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3849974-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | VTVX HOLDINGS II LLC | 2021-06-24 | — | — | US | disclosed |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | VTV THERAPEUTICS LLC (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2007107550-A1 | ADAMANTANE DERIVATIVES FOR THE TREATMENT OF THE METABOLIC SYNDROME | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007101864-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY, THEIR PREPARATION AND USE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2007-09-13 | — | — | WO | disclosed |
| WO-2007071766-A2 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | TRANSTECH PHARMA (US) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007003581-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003604-A2 | HISTS1MINE H3 RECEPTOR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006087309-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
| US-6140333-A | FOR TREATMENT AND/OR PROPHYLAXIS OF DISEASES INCLUDE SUCH RESPIRATORY DISEASES AS CHRONIC OBSTRUCTIVE PULMONARY DISEASES, CHRONIC BRONCHITIS, ASTHMA, CHRONIC RESPIRATORY OBSTRUCTION, PULMONARY FIBROSIS, PULMONARY EMPHYSEMA | BANYU PHARMACEUTICAL CO LTD (JP) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112187-A1 | PYRAZOLOPYRIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | SSB, KCNJ1, KCNJ11 | ALDH1A1 1043/4885CYP2D6 1180/4885CYP3A4 1728/4885 |
| US-10947180-B2 | Phenoxy acetic acids and phenyl propionic acids as PPAR delta agonists | PPARG, PPARA, PPARD | ALDH1A1 487/4885CYP2D6 2274/4885CYP3A4 995/4885 |
| US-20210188758-A1 | PHENOXY ACETIC ACIDS AND PHENYL PROPIONIC ACIDS AS PPAR DELTA AGONISTS | PPARG, PPARA, PPARD | ALDH1A1 487/4885CYP2D6 2274/4885CYP3A4 995/4885 |
| US-20100179154-A1 | 6-CYCLOAMINO-3-(PYRID-4-YL)IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CBR3, DHFR, IL4I1 | ALDH1A1 586/4885CYP2D6 94/4885CYP3A4 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.